share_log

Soligenix Reveals Formation Of European Medical Advisory Board To Provide Additional Medical/Clinical Strategic Guidance; Phase 3 Clinical Study Of HyBryte In CTCL Initiating In 2024

Soligenix Reveals Formation Of European Medical Advisory Board To Provide Additional Medical/Clinical Strategic Guidance; Phase 3 Clinical Study Of HyBryte In CTCL Initiating In 2024

soligenix透露成立欧洲医疗顾问委员会,提供额外的医疗/临床战略指导;HyBryte在2024年开始进行CTCL的第三阶段临床研究。
Benzinga ·  2024/11/19 06:40

Soligenix Reveals Formation Of European Medical Advisory Board To Provide Additional Medical/Clinical Strategic Guidance; Phase 3 Clinical Study Of HyBryte In CTCL Initiating In 2024

Soligenix公布成立欧洲医疗顾问委员会,以提供额外的医疗/临床战略指导;HyBryte在CTCL的第三阶段临床研究将于2024年启动。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发